News from sanofi canada A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 17, 2020, 07:00 ET DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma

Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral corticosteroid-dependent asthma Fourth indication for DUPIXENT® in Canada following approvals for ...


Sep 22, 2020, 12:16 ET Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

Signed agreements relate to vaccine candidate using Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant Both companies are committed to making their COVID-19 vaccine...


Aug 18, 2020, 07:00 ET DUPIXENT® (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis

First biologic approved in Canada for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP)1 Third indication for DUPIXENT® in Canada following moderate-to-severe atopic dermatitis...


Jul 14, 2020, 08:00 ET DUPIXENT® (dupilumab) receives positive recommendation from INESSS for the treatment of moderate-to-severe atopic dermatitis in adolescents

The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec to include patients aged 12 years and older Recommendation was supported...


Jul 08, 2020, 07:15 ET SARCLISA™ (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma

First and only anti-CD38 antibody in combination with pomalidomide and dexamethasone (pom-dex) to be approved in Canada1,2 SARCLISA™ in combination with pom-dex significantly reduced the risk of...


Mar 02, 2020, 11:25 ET Cablivi® (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura (aTTP)

Cablivi® is the first treatment approved in Canada for aTTP, a life-threatening blood clotting disorder It's estimated that up to 20% of patients die from TTP episodes, despite currently available...


Oct 22, 2019, 09:00 ET Patients in Quebec now have access to DUPIXENT™ for the treatment of moderate-to-severe atopic dermatitis

* Quebec becomes the first province to list DUPIXENT™ for public reimbursement in adult patients TORONTO, Oct. 22, 2019 /CNW/ - Patients living in Quebec will now have access, through the Régie de...


Oct 01, 2019, 09:00 ET "Pillars of Strength" photo exhibit opens to celebrate National Seniors Day with compelling images of Canadian Seniors

National Seniors Day event celebrates seniors and raises awareness of the burden of flu in seniors and the domino effect it has on their lives. The flu has a significant impact that can put seniors...


Sep 27, 2019, 09:44 ET Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis

Dupixent™ can significantly reduce the constant itch and improve the skin's overall condition1 TORONTO, Sept. 27, 2019 /CNW/ - Health Canada has approved Dupixent™ (dupilumab) for the treatment of...


Oct 17, 2018, 07:00 ET Canadians are invited to join the conversation: Raise Your Hand for Diabetes

LAVAL, QC, Oct. 17, 2018 /CNW Telbec/ - Sanofi Canada is on a mission to raise awareness and money to help people living with diabetes, one of the leading causes of death and disability in Canada.1...


Sep 27, 2018, 16:55 ET Canadians living with diabetes in Ontario and Manitoba now have greater access to diabetes medicine

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) * Toujeo® receives provincial formulary coverage in Ontario * Lantus® gains improved provincial formulary coverage in Manitoba LAVAL, QC, Sept. 27, 2018...


Jul 10, 2018, 07:02 ET Sanofi denounces CADTH negative recommendation that could limit treatment options for Canadians with atopic dermatitis

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) * CADTH recommendation for Dupixent™ disregards patient input and ignores clinical value LAVAL, QC, July 10, 2018 /CNW Telbec/ - Sanofi Genzyme is...


Jun 13, 2018, 07:23 ET Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Three-quarters of employers are worried about the impact of unmanaged chronic disease Two-thirds (66%) of Canadian employees would consent to receive...


Jun 08, 2018, 08:00 ET Canadian science prodigy winner of prestigious international competition

Sajeev Kohli, a Grade 11 student from Waterloo, Ontario, receives top honours in the Global Healthcare Challenge LAVAL, QC, June 7, 2018 /CNW Telbec/ - Sajeev Kohli, a grade 11 student science...


May 16, 2018, 07:00 ET Canadians living with diabetes can now access a new resource to help better manage their disease

LAVAL, QC, May 16, 2018 /CNW/ - Sanofi and Sun Life Financial are pleased to announce a new program that provides Canadians living with diabetes access to health information related to the use of...


Apr 12, 2018, 17:20 ET Sanofi to invest €350 million in Canadian vaccine facility

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Expansion demonstrates company's commitment to innovation and leadership in global public health New Toronto facility is one of the largest-ever investments ...


Apr 12, 2018, 08:00 ET New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels

* Panel of Canadian experts recommend new ways to overcome barriers Canadians face when trying to achieving their target glucose (blood sugar) levels.1 LAVAL, QC, April 12, 2018 /CNW Telbec/ - Faced...


Apr 11, 2018, 07:00 ET /R E P E A T -- Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility/

TORONTO, April 10, 2018 /CNW Telbec/ - Sanofi invites members of the media to the announcement of a landmark investment in lifesaving vaccine production in Canada. The investment will cement the...


Apr 10, 2018, 11:00 ET Media Advisory - Sanofi to announce significant investment in Canadian vaccine production facility

TORONTO, April 10, 2018 /CNW Telbec/ - Sanofi invites members of the media to the announcement of a landmark investment in lifesaving vaccine production in Canada. The investment will cement the...


Dec 12, 2017, 13:12 ET The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

Results of studies comparing Sanofi's Toujeo® and insulin degludec Clinical implications for people living with diabetes LAVAL, QC, Dec. 12, 2017 /CNW Telbec/ - Sanofi Canada announces the results of ...


Oct 17, 2017, 14:20 ET Insulin in People Living with Type 2 Diabetes: Initiation and Dosage

Favourable results from a scientific study conducted by Canadian investigators on the dosage adjustment of Toujeo® LAVAL, QC, Oct. 17, 2017 /CNW Telbec/ - Individuals with type 2 diabetes may need...


May 29, 2017, 09:09 ET The 20th Anniversary of The Sanofi Canada Healthcare Survey reveals surprising facts

Employees not as happy with health benefits as past years & are more willing to give access to personal data MONTREAL, May 29, 2017 /CNW Telbec/ - The 20th anniversary of The Sanofi Canada Healthcare ...


May 12, 2017, 12:42 ET Université de Montréal Doctoral Student earns Global Nursing Innovation Award

LAVAL, QC, May 12, 2017 /CNW/ - The Connecting Nurses Patient Centricity program is proud to announce that Guillaume Fontaine, a Montreal-based graduate student and registered nurse, will be a...


May 26, 2016, 16:17 ET U.S.FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 - ...


May 24, 2016, 11:02 ET New Cholesterol Treatment Now Available for Canadians

As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENT™ MONTREAL, May 24, 2016 /CNW Telbec/ - Sanofi Canada is pleased to...